US court narrows rules for judging patent disputes:
This article was originally published in Clinica
Executive Summary
In a ruling that impinges on the medical device industry, the US Federal Appeals Court has said that state adjudication in intellectual property matters cannot rely on common law standards such as fraud, but can only be judged by US patent law. The US Court of Appeals for the Federal Circuit reversed a $45 million decision against American Cyanamid last week which was based on claims of fraudulent non-disclosure and unjust enrichment alleged by two doctors from the University of Colorado.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.